A detailed history of Adirondack Trust CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Adirondack Trust CO holds 449 shares of VRTX stock, worth $225,600. This represents 0.08% of its overall portfolio holdings.

Number of Shares
449
Previous 499 10.02%
Holding current value
$225,600
Previous $233,000 10.73%
% of portfolio
0.08%
Previous 0.1%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$460.0 - $505.78 $23,000 - $25,289
-50 Reduced 10.02%
449 $208,000
Q2 2024

Jul 09, 2024

SELL
$392.81 - $485.53 $3,535 - $4,369
-9 Reduced 1.77%
499 $233,000
Q4 2023

Mar 29, 2024

SELL
$343.0 - $410.68 $3,087 - $3,696
-9 Reduced 1.74%
508 $206,000
Q3 2023

Oct 31, 2023

SELL
$338.18 - $362.46 $13,527 - $14,498
-40 Reduced 7.18%
517 $179,000
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $3,144 - $3,519
-10 Reduced 1.76%
557 $196,000
Q1 2023

Apr 28, 2023

SELL
$283.23 - $323.1 $3,965 - $4,523
-14 Reduced 2.41%
567 $178,000
Q4 2022

Jan 13, 2023

BUY
$285.76 - $321.48 $30,290 - $34,076
106 Added 22.32%
581 $0
Q3 2022

Oct 13, 2022

BUY
$273.83 - $305.53 $15,882 - $17,720
58 Added 13.91%
475 $138,000
Q2 2022

Jul 06, 2022

BUY
$234.96 - $292.55 $30,309 - $37,738
129 Added 44.79%
417 $117,000
Q1 2022

Apr 05, 2022

BUY
$221.42 - $260.97 $50,040 - $58,979
226 Added 364.52%
288 $75,000
Q3 2021

Nov 16, 2021

BUY
$181.39 - $202.99 $6,711 - $7,510
37 Added 148.0%
62 $11,000
Q3 2019

Oct 09, 2019

SELL
$166.23 - $187.09 $13,298 - $14,967
-80 Reduced 76.19%
25 $4,000
Q3 2017

Oct 12, 2017

BUY
$148.13 - $162.24 $15,553 - $17,035
105
105 $16,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Adirondack Trust CO Portfolio

Follow Adirondack Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adirondack Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Adirondack Trust CO with notifications on news.